Ricardo Sanchez-Prieto

profesor asociado

University of Castilla-La Mancha

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Cancer Biology Cancer Biology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ricardo Sanchez-Prieto is an Associate Professor at Universidad de Castilla la Mancha in Spain. His research specialties include kinase signaling, radiosensitivity in cancer treatment, and the therapeutic implications of signaling pathways in sarcoma. Recent publications highlight his work on microtubule drug responses, the effectiveness of LDR brachytherapy, and novel aromatase inhibitors. He aims to contribute to advancements in cancer therapy and treatment methodologies.

Articles (16)

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

SPAIN

View details

Antonio Fernandez Aramburo

PROFESOR ASOCIADO

Universidad de Murcia Facultad de Medicina

SPAIN

View details

Julia Oxford

Professor

Boise State University

UNITED STATES

View details

Anna Massaguer

Associate Professor

Universitat de Girona

SPAIN

View details

María José Ruiz Hidalgo

Profesor Titular de Universidad

University of Castilla-La Mancha

SPAIN

View details

Francisco J. Cimas

University of Castilla-La Mancha

SPAIN

View details

Gregorio Castañeda Peñalvo

Profesor Titular de Universidad

University of Castilla-La Mancha

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ricardo Sanchez-Prieto

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Osmotic stress influences microtubule drug response via WNK1 kinase signaling

The CDK12-BRCA1 signaling axis mediates dinaciclib-associated radiosensitivity through p53-mediated cellular senescence.

Ferrozoles: Ferrocenyl derivatives of letrozole with dual effects as potent aromatase inhibitors and cytostatic agents

P38 MAPK and Radiotherapy: Foes or Friends?

LDR brachytherapy offers superior tumor control to single‐fraction HDR prostate brachytherapy: A prospective study

Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications.

MAPK11 (p38β) is a major determinant of cellular radiosensitivity by controlling ionizing radiation-associated senescence: An in vitro study

LDR brachytherapy offers superior tumor control to single-fraction HDR prostate brachytherapy: A prospective study

Ferrozoles: Ferrocenyl derivatives of letrozole with dual effects as potent aromatase inhibitors and cytostatic agents

Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications

P38 MAPK and Radiotherapy: Foes or Friends?

ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology

Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease.

Effect of the aniline fragment in Pt(II) and Pt(IV) complexes as anti-proliferative agents. Standard reduction potential as a more reliable parameter for Pt(IV) compounds than peak reduction potential.

ERK5 signalling pathway is a novel target of sorafenib: Implication in EGF biology.

p38β (MAPK11) mediates gemcitabine-associated radiosensitivity in sarcoma experimental models.

Collaborators (11)

Juan Ángel Organero Gallego

Sílvia Barrabés Vera

Gema Dura

Ana María Rodríguez Fernández-Pacheco

jose luis albasanz

Antonio Fernandez Aramburo

Julia Oxford

Anna Massaguer

María José Ruiz Hidalgo

Francisco J. Cimas

Gregorio Castañeda Peñalvo

Make your next move.